2026 World Conference on Lung Cancer (WCLC 2026)
Seoul 12 September 2026 - 15 September 2026
Sacituzumab govitecan plus pembrolizumab no better than monotherapy in metastatic NSCLC
Combination treatment with sacituzumab govitecan (SG) and pembrolizumab has resulted in a numerically longer progression-free survival (PFS) compared with pembrolizumab alone in patients with previously untreated metastatic nonsmall-cell lung cancer (NSCLC), but the difference did not reach statistical significance, according to the phase III EVOKE-03/KEYNOTE D46 study.
ARTEMIS-008: Risvutatug rezetecan shows promise as new standard of care for relapsed SCLC
Treatment with the B7-H3-directed antibody-drug conjugate risvutatug rezetecan (Ris-Rez) results in significant improvements in overall survival (OS) compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) who had progressed after receiving platinum-based chemotherapy, as shown by the results of the phase III ARTEMIS-008 trial.
No OS benefit to adding LCT after NIVO-IPI in metastatic NSCLC
Adding local consolidative therapy (LCT) after induction with nivolumab and ipilimumab does not improve survival in immunotherapy-naïve patients with metastatic non–small cell lung cancer (NSCLC), as shown in the phase III LONESTAR trial presented at WCLC 2026.
PAPILLON reports longest OS in EGFR ex20ins NSCLC with amivantamab–chemo
First-line (1L) amivantamab plus chemotherapy improves overall survival (OS) in patients with treatment-naïve, locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations, according to the results from the protocol-specified final OS analysis of the phase III PAPILLON study.
Novel EGFR inhibitor shows potential in REZILIENT 3
In the phase III REZILIENT* 3 trial, adding zipalertinib to chemotherapy improves progression-free survival (PFS) in patients with treatment-naïve metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 20 insertion mutations (ex20ins-mut).